Hikma cuts offer for Boehringer's U.S. generic drug unit by $535 mln
0
Feb 10 (Reuters) - Hikma Pharmaceuticals said it would now pay $535 million less than its earlier offer to buy Boehringer Ingelheim's U.S. generic drugs business after due diligence revealed that the unit's revenue for 2015 would be lower than it expected.